Related Experiment Video

Updated: Aug 5, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

2.9K

Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study)

Thea Bjune1, Thea Bjerkestrand Bøe2, Stig Arne Kjellevold3

  • 1Vear General Practitioner Group, Vear, Vestfold, Norway.

International Journal of Nephrology and Renovascular Disease
|March 24, 2023
PubMed

Insights

New potassium binders effectively manage hyperkalemia in chronic kidney disease patients, allowing continued renin-angiotensin-aldosterone system inhibitor therapy with few side effects.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • Hyperkalemia is a frequent complication of chronic kidney disease (CKD).
  • Hyperkalemia poses risks and often necessitates discontinuation of renin-angiotensin-aldosterone system inhibitors (RAASi).

Purpose of the Study:

  • To evaluate the efficacy and safety of new potassium binders in managing hyperkalemia.
  • To assess the ability to maintain RAASi treatment in patients with proteinuric CKD and/or congestive heart failure (CHF).

Main Methods:

  • Retrospective cohort study of long-term potassium binder users.
  • Inclusion criteria: patients aged 18+, treated with potassium binders, meeting RAASi treatment indications and reimbursement criteria.

Main Results:

  • No hospital admissions for hyperkalemia post-initiation of potassium binders.
  • Significant reduction in maximum potassium levels observed.
  • All patients successfully maintained on RAASi therapy.
  • Minimal side effects and good tolerance reported.

Conclusions:

  • New potassium binders offer a safe and effective treatment for hyperkalemia.
  • These agents facilitate continued RAASi therapy, crucial for managing CKD and CHF.
Abstract

Keywords:
CKDRAASichronic kidney diseasehyperkalemiapotassium-binderrenin-angiotensin-aldosterone system inhibitors

More Related Videos

Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique07:19

Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique

Published on: February 7, 2025

381
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.1K

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
670
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
793
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
232
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
659